Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

. Based on the current expected level of receipts and expenditures, the company believes that its cash and cash equivalents are sufficient to support its activities into the fourth quarter of fiscal year 2009. The company will be eligible to receive a minimum milestone payment of $20 million from its U.S. partner, Strativa Pharmaceuticals, in the event that the planned NDA submission results in the company receiving marketing approval for ONCONASE.

Clinical/Regulatory Update

Alfacell has completed patient enrollment in a confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from unresectable malignant mesothelioma (UMM) and reached the required number of evaluable events to conduct the formal statistical analyses required to complete the final sections of the ONCONASE rolling NDA. As the company has previously reported, the results of the preliminary statistical analysis of the data did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need. Alfacell has requested a pre-NDA meeting with the Food and Drug Administration (FDA) to discuss the details of the planned NDA submission. The company continues to estimate that the final components of the rolling NDA will be submitted by the end of 2008, and the company plans to present the results of the Phase IIIb trial at an upcoming scientific conference in 2009.

The company has completed enrollment in its Phase I clinical trials for patients suffering from non-small cell lung cancer (NSCLC) and other solid tumors and is planning for a follow-on Phase II clinical trial in NSCLC patients that exhibit resistance to platinum based chemotherapy regimens. Initiation of patient enrollment in this tria
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... --  SunTrust Robinson Humphrey (STRH) today announced ... equity research team in biotechnology and oilfield services.  ... research demonstrates our commitment to providing our valued ... investment decision making," said Biff Woodruff , ... make significant investments in differentiated content at a ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/27/2014)... Salt Lake City, Utah (PRWEB) August 27, 2014 ... new construction that will expand its current Salt Lake ... operations currently underway outside of Utah to ultimately create ... the next 20 years. , “Utah is home ... many of whom can be credited with Varian’s success ...
(Date:8/27/2014)... 2014   MSC , a healthcare performance improvement ... the appointment of Mary Beth Loesch to ... of experience preparing companies for rapid growth and market ... President of Corporate Development and Healthcare. In that role, ... as well as corporate strategy and marketing. Previously, Loesch ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3MSC names Mary Beth Loesch President and CEO 2
... Today, Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced ... issued an approvable letter for Once-A-Day,LUVOX(R) CR (fluvoxamine ... Pharmaceuticals, Inc. are seeking marketing,approval for the treatment ... obsessive compulsive disorder (OCD)., The FDA requested ...
... Protein Exports, and Biofuels Key Issues in 2008, ... country,of origin labeling and developments in biofuels are some ... & Agribusiness Outlook., The Outlook is produced annually ... provides information and analysis covering all of,the major sectors ...
... SOUTH SAN FRANCISCO, Calif., Dec. 21 Anesiva,Inc. ... of its public offering,of 11,111,111 shares of its ... their option to purchase an additional 1,234,568 shares.,The ... from the sale of the aggregate 12,345,679 shares ...
Cached Biology Technology:FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 2Rabobank Releases Annual North American Food & Agribusiness Outlook 2Rabobank Releases Annual North American Food & Agribusiness Outlook 3Rabobank Releases Annual North American Food & Agribusiness Outlook 4
(Date:8/28/2014)... the most commonly diagnosed learning disability in the ... occurs when the regions of the brain that ... use of non-invasive functional neuroimaging tools has helped ... However, most prior work has focused on only ... gap in our understanding of how multiple brain ...
(Date:8/28/2014)... mould in homes could pose a significant health risk to ... the Journal of Allergy and Clinical Immunology . , ... different countries, the research has found that the presence of ... asthma sufferers, as well as increasing the likelihood of developing ... team at the University of Exeter Medical School and is ...
(Date:8/28/2014)... more action is needed to ensure safeguards are in ... in PLOS ONE , researchers from Monash University, ... - combining results from different studies - to look ... areas, to determine whether they actually protect biodiversity. ... protecting an area from human exploitation made common sense, ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2Indoor mold poses health risk to asthma sufferers 2Protected areas proven to protect biodiversity 2
... innovative systems biology approach to understanding the carbohydrate structures ... how inflammatory illnesses and cardiovascular disease develop in humans. ... University at Buffalo chemical engineers. , Supported by ... ultimate goal of the project is to define novel ...
... Eastman Dental Center,s Hyun (Michel) Koo, D.D.S, Ph.D., $1.6 ... the single most prevalent and costly oral infectious disease ... results from the interaction of specific bacteria (such as ... using sucrose to help them, and other pathogens, to ...
... N.J. Dr. Dilhan Kalyon, Professor of Chemical ... Institute at Stevens Institute of Technology, has won ... The award, sponsored by Shell Global Solutions, Inc., ... made a significant impact in the field of ...
Cached Biology News:Researchers apply systems biology and glycomics to study human inflammatory diseases 2Researchers apply systems biology and glycomics to study human inflammatory diseases 3Eastman Dental Center awarded $1.6 million to find ways to prevent cavities 2